Azithromycin | Placebo | Difference | 95% CI | p Value | |
---|---|---|---|---|---|
SGRQ | (n = 37) | (n = 37) | |||
Total score | −6.6 ± 1.8 | 0.9 ±1.8 | −7.5 ± 2.5 | −12.5;-2.5 | 0.004 |
Symptoms | −9.2 ± 3.0 | 0.1 ± 3.0 | −9.1 ± 4.2 | −17.6;-.07 | 0.034 |
Activity | −4.1 ± 2.3 | 0.2 ± 2.3 | −4.3 ± 3.2 | −10.7;2.1 | 0.18 |
Impact | −7.3 ± 2.0 | 1.6 ± 2.0 | −8.9 ± 2.8 | −14.5;-3.3 | 0.002 |
SF-36 | (n = 37) | (n = 37) | |||
General health* | 4.5 ± 2.4 | −3.8 ± 2.4 | 8.3 ± 3.4 | 1.6;15 | 0.016 |
Physical functioning | 5.5 ± 2.2 | 0.7 ± 2.3* | 4.8 ± 3.2 | −1.5;11.1 | 0.13 |
Bodily pain | 5.6 ± 3.3 | −0.9 ± 3.3 | 6.5 ± 4.7 | −2.9;15.9 | 0.17 |
Vitality* | 4.0 ± 2.4 | −2.0 ± 2.4 | 6.0 ± 3.4 | −0.8;12.9 | 0.08 |
Role physical | 16.2 ± 5.4 | −1.1 ± 5.4 | 17.3 ± 7.6 | 2.2;32.5 | 0.025 |
Role emotional | −0.4 ± 5.6 | −6.3 ± 5.6 | 5.9 ± 7.9 | −9.8;21.7 | 0.46 |
Social functioning | 4.4 ± 3.1 | −8.5 ± 3.1 | 12.9 ± 4.4 | 4.0;21.7 | 0.005 |
Mental health* | 2.2 ± 1.9 | −3.5 ± 1.9 | 5.7 ± 2.7 | 0.4;11.0 | 0.037 |